Laura A M Duineveld1, Kristel M van Asselt2, Willem A Bemelman3, Anke B Smits4, Pieter J Tanis3, Henk C P M van Weert2, Jan Wind2. 1. Department of Primary Care, Academic Medical Centre, Amsterdam, the Netherlands l.a.duineveld@amc.uva.nl. 2. Department of Primary Care, Academic Medical Centre, Amsterdam, the Netherlands. 3. Department of Surgery, Academic Medical Centre, Amsterdam, the Netherlands. 4. Department of Surgery, St Antonius Hospital, Nieuwegein, the Netherlands.
Abstract
PURPOSE: Follow-up after colorectal cancer treatment with curative intent aims to detect recurrences and metachronous tumors in a timely manner. The objective of this study is to assess how recurrent disease presents and is diagnosed within scheduled follow-up according to the national guideline for the Netherlands. METHODS: In a retrospective study of consecutive patients with colorectal cancer who were treated in 2 hospitals in the Netherlands, we identified patients with colon cancer who underwent surgery with curative intent between January 2007 and December 2012. Patients who developed recurrent disease were included for further analyses. RESULTS: From a total of 446 patients who were been treated for colon carcinoma with curative intent, 74 developed recurrent disease (17%). In 43 of those patients (58%), recurrent disease was detected during a scheduled follow-up visit, with 41 (95%) being asymptomatic. Tumor marker testing, imaging, and colonoscopy identified all of these recurrences. In the remaining 31 patients with recurrent disease (42%), recurrence was found during non-scheduled interval visits; 26 (84%) of these patients were symptomatic. The most prevalent symptoms were abdominal pain, altered defecation, and weight loss. Patients with asymptomatic recurrences had a significantly higher overall survival compared with patients with symptomatic recurrences. CONCLUSIONS: In this cohort, 42% of the recurrences after initial curative treatment for colon cancer were found during non-scheduled interval visits, mainly based on symptoms. Primary care physicians who take care of patients whose colon cancer might recur should be aware of the relatively high rate of symptomatic recurrences and of typical presenting symptoms.
PURPOSE: Follow-up after colorectal cancer treatment with curative intent aims to detect recurrences and metachronous tumors in a timely manner. The objective of this study is to assess how recurrent disease presents and is diagnosed within scheduled follow-up according to the national guideline for the Netherlands. METHODS: In a retrospective study of consecutive patients with colorectal cancer who were treated in 2 hospitals in the Netherlands, we identified patients with colon cancer who underwent surgery with curative intent between January 2007 and December 2012. Patients who developed recurrent disease were included for further analyses. RESULTS: From a total of 446 patients who were been treated for colon carcinoma with curative intent, 74 developed recurrent disease (17%). In 43 of those patients (58%), recurrent disease was detected during a scheduled follow-up visit, with 41 (95%) being asymptomatic. Tumor marker testing, imaging, and colonoscopy identified all of these recurrences. In the remaining 31 patients with recurrent disease (42%), recurrence was found during non-scheduled interval visits; 26 (84%) of these patients were symptomatic. The most prevalent symptoms were abdominal pain, altered defecation, and weight loss. Patients with asymptomatic recurrences had a significantly higher overall survival compared with patients with symptomatic recurrences. CONCLUSIONS: In this cohort, 42% of the recurrences after initial curative treatment for colon cancer were found during non-scheduled interval visits, mainly based on symptoms. Primary care physicians who take care of patients whose colon cancer might recur should be aware of the relatively high rate of symptomatic recurrences and of typical presenting symptoms.
Authors: Yvette R B M van Gestel; Ignace H J T de Hingh; Myrthe P P van Herk-Sukel; Felice N van Erning; Laurens V Beerepoot; Jan H Wijsman; Gerrit D Slooter; Harm J T Rutten; Geert-Jan M Creemers; Valery E P P Lemmens Journal: Cancer Epidemiol Date: 2014-05-17 Impact factor: 2.984
Authors: Daniel J Sargent; Harry S Wieand; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; Charles D Blanke; David Kerr; Erin Green; Norman Wolmark; Thierry Andre; Richard M Goldberg; Aimery De Gramont Journal: J Clin Oncol Date: 2005-10-31 Impact factor: 44.544
Authors: D A Wattchow; D P Weller; A Esterman; L S Pilotto; K McGorm; Z Hammett; C Platell; C Silagy Journal: Br J Cancer Date: 2006-04-24 Impact factor: 7.640
Authors: John N Primrose; Rafael Perera; Alastair Gray; Peter Rose; Alice Fuller; Andrea Corkhill; Steve George; David Mant Journal: JAMA Date: 2014-01-15 Impact factor: 56.272
Authors: R Vera; J Aparicio; F Carballo; M Esteva; E González-Flores; J Santianes; F Santolaya; J M Fernández-Cebrián Journal: Clin Transl Oncol Date: 2019-02-14 Impact factor: 3.405
Authors: Ellen M Goldberg; Yaniv Berger; Divya Sood; Katherine C Kurnit; Josephine S Kim; Nita K Lee; S Diane Yamada; Kiran K Turaga; Oliver S Eng Journal: Ann Surg Oncol Date: 2021-05-06 Impact factor: 5.344
Authors: Thijs Wieldraaijer; Pascal Bruin; Laura A M Duineveld; Pieter J Tanis; Anke B Smits; Henk C P M van Weert; Jan Wind Journal: Dig Surg Date: 2017-03-14 Impact factor: 2.588
Authors: Kevin Chen; Misty D Shields; Pradeep S Chauhan; Ricardo J Ramirez; Peter K Harris; Melissa A Reimers; Jose P Zevallos; Andrew A Davis; Bruna Pellini; Aadel A Chaudhuri Journal: Mol Diagn Ther Date: 2021-11-01 Impact factor: 4.476